Unknown

Dataset Information

0

Effect of early prophylactic low-dose recombinant human erythropoietin on retinopathy of prematurity in very preterm infants.


ABSTRACT: Background: Very preterm infants are at risk of developing retinopathy of prematurity (ROP). Recombinant human erythropoietin (rhEPO) is routinely used to prevent anemia in preterm infants; however, the effect of rhEPO on ROP development is still controversial. The purpose of this study was to evaluate the effect of early prophylactic low-dose rhEPO administration on ROP development in very preterm infants.

Methods: A total of 1898 preterm infants born before 32 weeks of gestation were included. Preterm infants received rhEPO (n?=?950; 500 U/kg, rhEPO group) or saline (n?=?948, control group) intravenously within 72 h of birth and then once every other day for 2 weeks.

Results: The total incidence of ROP was not significantly different between the two groups (10.2% vs. 13.2%, p?=?0.055). Further analysis showed that rhEPO group had lower rates of type 2 ROP than the control group (2.2% vs. 4.1%, RR 0.98; 95% CI 0.96-1.00; p?=?0.021). Subgroup analysis found that rhEPO treatment significantly decreased the incidence of type 2 ROP in infant boys (1.8% vs. 4.3%, p?=?0.021) and in those with a gestational age of 28-296/7 weeks (1.1% vs. 4.9%, p?=?0.002) and birth weight of 1000-1499 g (1.2% vs. 4.2%, p?=?0.002). There was a small increasing tendency for the incidence of ROP in infants with a gestational age of?
Conclusions: Repeated low-dose rhEPO administration has no significant influence on the development of ROP; however, it may be effective for type 2 ROP in infant boys or in infants with gestational age?>?28 weeks and birth weight?>?1500 g. Trial registration The data of this study were retrieved from two clinical studies registered ClinicalTrials.gov (NCT02036073) on January 14, 2014, https://clinicaltrials.gov/ct2/show/NCT02036073 ; and (NCT03919500) on April 18, 2019. https://clinicaltrials.gov/ct2/show/NCT03919500 .

SUBMITTER: Sun H 

PROVIDER: S-EPMC7574422 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effect of early prophylactic low-dose recombinant human erythropoietin on retinopathy of prematurity in very preterm infants.

Sun Huiqing H   Song Juan J   Kang Wenqing W   Wang Yong Y   Sun Xiantao X   Zhou Chongchen C   Xiong Hong H   Xu Falin F   Li Mingchao M   Zhang Xiaoli X   Yu Zengyuan Z   Peng Xirui X   Li Bingbing B   Xu Yiran Y   Xing Shan S   Wang Xiaoyang X   Zhu Changlian C  

Journal of translational medicine 20201019 1


<h4>Background</h4>Very preterm infants are at risk of developing retinopathy of prematurity (ROP). Recombinant human erythropoietin (rhEPO) is routinely used to prevent anemia in preterm infants; however, the effect of rhEPO on ROP development is still controversial. The purpose of this study was to evaluate the effect of early prophylactic low-dose rhEPO administration on ROP development in very preterm infants.<h4>Methods</h4>A total of 1898 preterm infants born before 32 weeks of gestation w  ...[more]

Similar Datasets

| S-EPMC5084793 | biostudies-literature
| S-EPMC8173165 | biostudies-literature
| S-EPMC7180729 | biostudies-literature
| S-EPMC4057649 | biostudies-literature
| S-EPMC6855825 | biostudies-literature
| S-EPMC7566718 | biostudies-literature